Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1081737 | 0.91 | ADORA2A (0.68) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| Hydrochloric Acid SCHEMBL6754869 | 0.90 | ADORA2A (0.68) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| Hydrochloric Acid SCHEMBL2031971 | 0.90 | ADORA2A (0.67) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| SCHEMBL2295172 | 0.88 | ADORA2A (0.65) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| SCHEMBL940189 | 0.86 | ADORA2A (0.55) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| SCHEMBL5964634 | 0.84 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3695466 | 0.83 | ADORA3 (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1976908 | 0.83 | ADORA2A (0.56) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| SCHEMBL29354597 | 0.83 | ADORA2A (0.83) | ADORA2AADORA3ADORA1KDM4EADORA2B | |
| SCHEMBL8095238 | 0.83 | ADORA2A (0.83) | ADORA2AADORA3ADORA1KDM4EADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153781-B2 | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-10 | — | — | US | claimed |
| EP-2170401-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2010-04-07 | — | — | EP | claimed |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA (US) | 2009-01-08 | — | — | US | claimed |
| WO-2009006046-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | claimed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | SITKOVSKY MICHAIL V (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2608794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | Northeastern University (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8153781-B2 | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-10 | — | — | US | disclosed |
| WO-2012027695-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | NORTHEASTERN UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2170401-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009152431-A1 | P2Y1 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009006046-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA3 3/4885ADORA1 1/4885 |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.